Eight Genotypes and 84 Subtypes of HCV

The hepatitis C virus (HCV) is classified into 7 genotypes and 67 subtypes. Knowing the HCV genotype and subtype has been really important in determining the optimal treatment regimen. A study presented at The AASLD Liver Meeting 2017 – “Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir Based Regimens” – found 17 novel HCV subtypes and 1 novel HCV genotype, unrelated to each other and to previously described HCV subtype

The Week in Review: October 27 – November 4, 2017

Friday, November 4, 2017 News Recap: Access to Treatment Hepatitis C could be eliminated in Canada, but drug prices, screening barriers stand in the way – Most of the 70 million patients infected with hepatitis C worldwide could be cured for $50 US each Many countries — including Canada — have committed to a global goal of eliminating hepatitis C by 2030. But new data released at the summit in Brazil shows that only nine countries are on track to me...

Curing hepatitis C with DAAs linked to 71% reduction in liver cancer

People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, according to study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC. "It doesn’t matter how you eradicate hepatitis C, you get a similar reduction in liver cancer," George Ioannou of the

The Week in Review: October 20 – October 27, 2017

Friday, October 27, 2017 News Recap: Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6. We need to hear your voice by November 8, 2017!  AbbVie’s “GP” combo is pan-genotypic (works for all genotypes). Liver Meeting 2017: I’m A HCV Patient – Show Me What I Need to Know! Why reinvent the wheel? The good folks over at HCV New Drugs have put together this great overview o...

Liver Meeting 2017: I’m A HCV Patient – Show Me What I Need To Know!

Why reinvent the wheel? The good folks over at HCV New Drugs have put together this great overview of what happened at the AASLD Conference (2017) using easy to follow video clips, and future learning activities. Quick Review  Jump over to Practice Point, sit back and watch 5 minute video clips reviewing each day of the meeting. The good doctor, Mark Sulkowski, will discuss SVR results, toxicity/adverse events, drug interactions, and HCV management. Alth

DAA Era Linked with Better Liver Transplant Outcomes

HCV treatment improvements reflected in graft, patient survival WASHINGTON -- Patients with chronic hepatitis C have done better after liver transplant in the era of direct-acting agents (DAAs) against the virus, a researcher said here. In a retrospective analysis of transplant outcomes, the DAA era was associated with a 36% drop in mortality a year after transplant, according to George Cholankeril, MD, of the University of Tennessee Health Science Cen

AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017

- 16 HCV abstracts to be presented including 12 data presentations on the safety and efficacy of MAVYRET - MAVYRET is recommended in new AASLD guidelines as a first line treatment option for 8 weeks in treatment-naïve non-cirrhotic HCV patients across all genotypes (GT1-6) NORTH CHICAGO, Ill., Oct. 11, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced that it wi...